842 related articles for article (PubMed ID: 18070166)
21. The sting challenge test in Hymenoptera venom allergy: pros and cons.
Bilò MB; Brianzoni MF; Garritani MS; Antonicelli L; Farabollini B; Bonifazi F
Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):377-81. PubMed ID: 14768522
[TBL] [Abstract][Full Text] [Related]
22. [Clinical and biological surveillance after the cessation of Hymenoptera venom desensitization].
Touraine F; Talayrach D; Florea O; Brianchon Ch; Preux PM; Bonnaud F
Eur Ann Allergy Clin Immunol; 2003 Nov; 35(9):335-9. PubMed ID: 14716961
[TBL] [Abstract][Full Text] [Related]
23. Follow-up of venom immunotherapy (VIT) based on conventional techniques and monitoring of immunoglobulin E to individual venom allergens.
Carballada F; Boquete M; Núñez R; Lombardero M; de la Torre F
J Investig Allergol Clin Immunol; 2010; 20(6):506-13. PubMed ID: 21243935
[TBL] [Abstract][Full Text] [Related]
24. Expansion of FOXP3-positive CD4+CD25+ T cells associated with disease activity in atopic dermatitis.
Ito Y; Adachi Y; Makino T; Higashiyama H; Fuchizawa T; Shimizu T; Miyawaki T
Ann Allergy Asthma Immunol; 2009 Aug; 103(2):160-5. PubMed ID: 19739430
[TBL] [Abstract][Full Text] [Related]
25. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
[TBL] [Abstract][Full Text] [Related]
26. Gene expression analysis in predicting the effectiveness of insect venom immunotherapy.
Niedoszytko M; Bruinenberg M; de Monchy J; Wijmenga C; Platteel M; Jassem E; Oude Elberink JN
J Allergy Clin Immunol; 2010 May; 125(5):1092-7. PubMed ID: 20334904
[TBL] [Abstract][Full Text] [Related]
27. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients.
Lerch E; Müller UR
J Allergy Clin Immunol; 1998 May; 101(5):606-12. PubMed ID: 9600496
[TBL] [Abstract][Full Text] [Related]
28. [Value of specific IgE and IgG4 measurements in the follow-up of a hymenoptera venom immunotherapy treatment: apropos of 82 cases].
Sonneville A; Loustanau O; Tahar HA; Menelet I
Allerg Immunol (Paris); 2000 Jan; 32(1):20-5. PubMed ID: 10723532
[TBL] [Abstract][Full Text] [Related]
29. Development of new IgE specificities to hymenoptera allergens during venom-specific immunotherapy.
Tavares B; Rordigues F; Pereira C; Loureiro G; Chieira C
Eur Ann Allergy Clin Immunol; 2005 May; 37(5):171-6. PubMed ID: 15984315
[TBL] [Abstract][Full Text] [Related]
30. Adverse reactions to venom immunotherapy.
Ramirez DA; Londono S; Evans R
Ann Allergy; 1981 Dec; 47(6):435-9. PubMed ID: 7325415
[TBL] [Abstract][Full Text] [Related]
31. Hymenoptera sting anaphylaxis: detection and clinical significance of individual bee and wasp venoms specific IgE and IgG4 antibodies.
Ameno S; Ameno K; Fuke C; Shinohara T; Kiriu T; Kinoshita H; Ijiri I
Nihon Hoigaku Zasshi; 1993 Jun; 47(3):207-12. PubMed ID: 8345683
[TBL] [Abstract][Full Text] [Related]
32. High sensitivity of basophils predicts side-effects in venom immunotherapy.
Kosnik M; Silar M; Bajrovic N; Music E; Korosec P
Allergy; 2005 Nov; 60(11):1401-6. PubMed ID: 16197472
[TBL] [Abstract][Full Text] [Related]
33. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
34. [Allergic reactions to insect bites].
Urbanek R
Ther Umsch; 1989 Sep; 46(9):654-62. PubMed ID: 2678576
[TBL] [Abstract][Full Text] [Related]
35. Expression of Th1, Th2, lymphocyte trafficking and activation markers on CD4+ T-cells of Hymenoptera allergic subjects and after venom immunotherapy.
Cabrera CM; Urra JM; Alfaya T; Roca Fde L; Feo-Brito F
Mol Immunol; 2014 Nov; 62(1):178-85. PubMed ID: 25004111
[TBL] [Abstract][Full Text] [Related]
36. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety.
Kalogeromitros D; Makris M; Koti I; Chliva C; Mellios A; Avgerinou G; Theoharides TC
Allergol Immunopathol (Madr); 2010; 38(2):69-73. PubMed ID: 19853357
[TBL] [Abstract][Full Text] [Related]
37. Regulatory T cell and cytokine changes in children undergoing 3 days rush venom immunotherapy.
Rattanamanee T; Lumjiaktase P; Kemawichanura N; Kiewgnam P; Jotikasthira W; Manuyakorn W
Asian Pac J Allergy Immunol; 2023 Sep; 41(3):193-198. PubMed ID: 33068370
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and clinical relevance of specific immunoglobulin E to pollen caused by sting- induced specific immunoglobulin E to cross-reacting carbohydrate determinants in Hymenoptera venoms.
Kochuyt AM; Van Hoeyveld EM; Stevens EA
Clin Exp Allergy; 2005 Apr; 35(4):441-7. PubMed ID: 15836751
[TBL] [Abstract][Full Text] [Related]
39. CD28 expression is increased in venom allergic patients but is not modified by specific immunotherapy.
Tsicopoulos A; Labalette M; Akoum H; Duez C; Wallaert B; Dessaint JP; Tonnel AB
Clin Exp Allergy; 1996 Oct; 26(10):1119-24. PubMed ID: 8911696
[TBL] [Abstract][Full Text] [Related]
40. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
